Shoshanna Zucker

Shoshanna Zucker, Ph.D. is the President and Chief Executive Officer of Haniva Technology LLC. Dr. Zucker received her Ph.D. in Molecular Pharmacology from Albert Einstein College of Medicine. She completed her postdoctoral studies at the University at Buffalo where she was a recipient of an NRSA fellowship studying gap junctions and cancer. She further pursued her research as a Senior Scientist at Roswell Park Cancer Institute where she studied gene regulation of oxidative stress and cancer. Currently, she is an Associate Professor in the School of Pharmacy and the Director of Research at D’Youville College. Dr. Zucker is actively involved in mentoring numerous students who participate in her research on oxidative stress, gap junctions, and cancer. In March 2017, Dr. Zucker received a Patent on Novel Combination Therapy for Cancer Research. The therapy combines the use of nonthermal plasma and DNA damaging agents activated by hypoxic conditions. Dr. Zucker is testing this therapy in models for melanoma, glioblastoma, and other cancer types. Dr. Zucker has a broad publication record in the fields of oxidative stress, gap junctions, and cancer.